Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.51 |
| ▸ | CCR3 | P51677 | 1/20 | 0.50 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GHSR | Q92847 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3081018 | 0.87 | ALDH1A1 (0.60) | CYP2D6CYP3A4KMT2AKDM4ESIGMAR1 | |
| SCHEMBL5242779 | 0.87 | OPRL1 (0.67) | CYP2D6CYP3A4KMT2AKDM4ESIGMAR1 | |
| Hydrochloric Acid SCHEMBL11194779 | 0.86 | ALDH1A1 (0.59) | CYP2D6CYP3A4KMT2AKDM4ESIGMAR1 | |
| SCHEMBL8751541 | 0.86 | KDM4E (0.56) | CYP2D6CYP3A4KMT2AKDM4EALDH1A1 | |
| SCHEMBL4272060 | 0.86 | SIGMAR1 (0.60) | CYP2D6CYP3A4SIGMAR1ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL10750648 | 0.85 | POLB (0.68) | CYP2D6CYP3A4KMT2AKDM4ESIGMAR1 | |
| SCHEMBL5166771 | 0.84 | ALDH1A1 (0.60) | CYP2D6CYP3A4KMT2AKDM4ESIGMAR1 | |
| SCHEMBL11191118 | 0.84 | KMT2A (0.56) | CYP2D6CYP3A4KMT2AKDM4EALDH1A1 | |
| SCHEMBL240629 | 0.84 | OPRL1 (0.73) | CYP2D6KMT2ASIGMAR1ALDH1A1TSHR | |
| SCHEMBL29017434 | 0.84 | CYP2D6 (0.57) | CYP2D6CYP3A4SIGMAR1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210121453-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-04-29 | — | — | US | disclosed |
| US-20210121453-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-04-29 | — | — | US | disclosed |
| US-20200163949-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-28 | — | — | US | disclosed |
| US-20200163949-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-28 | — | — | US | disclosed |
| US-20190314358-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190314358-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190117638-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-25 | — | — | US | disclosed |
| US-20190117638-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-25 | — | — | US | disclosed |
| CN-106061961-B | Selective N R2B antagonist | 百时美施贵宝公司 | 2018-12-18 | — | — | CN | disclosed |
| US-20180250283-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-06 | — | — | US | disclosed |
| US-20150191452-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | disclosed |
| US-20090062260-A1 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | IRM LLC (BM) | 2009-03-05 | — | — | US | disclosed |
| EP-1948636-A2 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | IRM LLC (BM) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007092065-A9 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | IRM LLC (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2007092065-A2 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | IRM LLC (BM) | 2007-08-16 | — | — | WO | disclosed |
| EP-0691956-A1 | 3-PHENYL-1,2,5,6-TETRAHYDROPYRIDINE DERIVATIVES AS SEDATIVES | LABORATOIRE L. LAFON (FR) | 1996-01-17 | — | — | EP | disclosed |
| WO-1994022827-A1 | 3-PHENYL-1,2,5,6-TETRAHYDROPYRIDINE DERIVATIVES AS SEDATIVES | LABORATOIRE L. LAFON (FR) | 1994-10-13 | — | — | WO | disclosed |
| EP-0200583-B1 | 7-HYDROXY INDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, USE AS MEDICINE, COMPOUNDS CONTAINING THEM AND THEIR INTERMEDIATES | ROUSSEL-UCLAF (FR) | 1991-06-12 | — | — | EP | disclosed |
| US-4736034-A | CARDIOTONIC AGENTS | ROUSSEL UCLAF (FR) | 1988-04-05 | — | — | US | disclosed |
| US-4694011-A | CARDIOVASCULAR DISORDERS | ROUSSEL UCLAF (FR) | 1987-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210121453-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | CYP2D6 2129/4885CYP3A4 3879/4885KMT2A 2824/4885 |
| US-20190117638-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | CYP2D6 2129/4885CYP3A4 3879/4885KMT2A 2824/4885 |
| US-20190314358-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | CYP2D6 2129/4885CYP3A4 3879/4885KMT2A 2824/4885 |
| US-20150191452-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | CYP2D6 2129/4885CYP3A4 3879/4885KMT2A 2824/4885 |
| US-20090062260-A1 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | NR1H2, NR1H3, NR1H4 | CYP2D6 865/4885CYP3A4 502/4885KMT2A 2392/4885 |
| US-20180250283-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | CYP2D6 2129/4885CYP3A4 3879/4885KMT2A 2824/4885 |
| US-20200163949-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | CYP2D6 2129/4885CYP3A4 3879/4885KMT2A 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.